文献速递白血病

急性髓系白血病高白细胞血症的管理及白细胞分离术对短期和长期临床结局的影响:一项大型、回顾性、多中心、国际研究

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
PubMed 文献 · Leukemia · 2020-03-04

该回顾性多中心国际研究纳入2006至2017年12个中心779例新诊断且WBC>50×10^9/L并接受强化化疗的AML患者,27%报告临床白细胞淤滞,15%接受白细胞分离术。30天死亡率为16.7%,中位OS为12.6个月,≥65岁患者为4.5个月。多因素分析中白细胞分离术未显著影响30天死亡率、CRc达成或OS。

要点

  • 白细胞分离术未显著改善30天死亡率、CRc或OS。
  • 临床白细胞淤滞者中白细胞分离术的获益仅见于未校正分析。
  • 需随机研究评估白细胞分离术的价值。

核心结论

  • 白细胞分离术未显著影响30天死亡率、CRc达成或OS。

研究设计与样本

  • 回顾性多中心国际研究,纳入2006至2017年12个中心779例新诊断AML且WBC>50×10^9/L并接受强化化疗的患者。

主要发现

  • 779例患者中,27%报告临床白细胞淤滞,15%接受白细胞分离术。
  • 30天死亡率为16.7%(95% CI: 13.9-19.3%)。
  • 所有患者中位OS为12.6个月(95% CI: 11.5-14.9),≥65岁患者为4.5个月(95% CI: 2.7-7.1)。
  • 多因素分析中白细胞分离术未显著影响30天死亡率、CRc达成或OS。
  • 在研究者判定的临床白细胞淤滞患者中,未校正分析显示白细胞分离术显著改善30天死亡率和OS,但多因素分析中不显著。

临床怎么用

  • 白细胞分离术的资源消耗、成本和潜在并发症显著,需随机研究评估其价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hyperleukocytosis in acute myeloid leukemia (AML) is associated with inferior outcomes. There is limited high quality evidence to support the benefits of leukapheresis. We retrospectively collected data from patients with newly-diagnosed AML who presented with a white cell count (WBC) >50 × 109/L to 12 centers in the United States and Europe from 2006 to 2017 and received intensive chemotherapy. Logistic regression models estimated odds ratios for 30-day mortality and achievement of composite complete remission (CRc). Cox proportional hazard models estimated hazard ratios for overall survival (OS). Among 779 patients, clinical leukostasis was reported in 27%, and leukapheresis was used in 113 patients (15%). Thirty-day mortality was 16.7% (95% CI: 13.9-19.3%). Median OS was 12.6 months (95% CI: 11.5-14.9) among all patients, and 4.5 months (95% CI: 2.7-7.1) among those ≥65 years. Use of leukapheresis did not significantly impact 30-day mortality, achievement of CRc, or OS in multivariate analysis based on available data or in analysis based on multiple imputation. Among patients with investigator-adjudicated clinical leukostasis, there were statistically significant improvements in 30-day mortality and OS with leukapheresis in unadjusted analysis, but not in multivariate analysis. Given the significant resource use, cost, and potential complications of leukapheresis, randomized studies are needed to evaluate its value.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020. PMID: 32132655. doi:10.1038/s41375-020-0783-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。